

At Tango Therapeutics, our approach to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer starts and ends with **patients**. Our team of passionate problem solvers is empowered by **collaboration, courage, and a culture of excellence** that values giving back to the community and protecting our shared environment.



**COMPANY**

**2 CLINICAL PROGRAMS**

*underway* for precision oncology therapeutics plus a promising pipeline of potential candidates in development.

**FOCUSED**

on addressing *previously undruggable genetic alterations in cancers*.

**COMPASSIONATE USE ACCESS**

to assist *patients unable to access PRMT5 trials*.



**LEADERSHIP**

**SCIENTIFIC ADVISORY BOARD**

*comprises renowned leaders* in oncology, molecular biology, pharmacology, and R&D.

**BOARD OF DIRECTORS**

*members possess diverse expertise* in biotech leadership, clinical development, commercialization, finance, venture capital, and scientific innovation.

**50%**

*of our Executive Committee members are women*.



**ASSOCIATES**

**TOGETHER @TANGO**

*team created* to advance our diversity, equity, inclusion, and belonging efforts.

**92%**

*stated that management cared about their well-being* and their work contributed to company goals, through the 2024 engagement survey.

**45%+**

*of Tango associates identify as persons of color*.



**COMMUNITY**

**30 BIKES**


*built and donated* to at-risk youth in the Boston area in 2024.

**\$120K+**

*raised by Tango to support local charities* benefiting at-risk youth in connection with the **Boston Marathon**, with eight Tango associates running.

**5 AMBULANCES**

*donated to aid* the Ukrainian people in war-torn areas.



**ENVIRONMENT**

**LEED GOLD,**

*Fitwel®, and WELL* certifications earned for our corporate headquarters.

**21 TONS**

*of waste diverted from landfills* through office composting in 2024; associate benefits include home composting reimbursement.

**LAB SUSTAINABILITY:**

ENERGY STAR® rated lab equipment and biohazard, plastics, and Styrofoam recycling program.



**BARBARA WEBER, MD**  
Chief Executive Officer

*“At Tango Therapeutics, we are united by a mission to deliver the next generation of precision oncology medicines. Responsible and ethical business practices serve as the cornerstone to how we will achieve that mission.*

*While it is early in our journey, we are dedicated to integrating environmental, social, and governance (ESG) principles into the fabric of our culture and our operations. To set the foundation, in 2024 we completed an in-depth ESG materiality assessment with input from key internal and external stakeholders to guide our ongoing efforts.*

*We are already integrating ESG principles across our business. As our clinical-stage programs progress, we are committed to ensuring that patients have access to these treatments through a transparent compassionate use program. In addition, we place emphasis on fostering a culture where diversity is valued. In our office, we strive to minimize our environmental footprint through robust recycling and sustainability measures. And, we have a tradition of coming together multiple times throughout the year as a company to give back to the community.*

*On a personal note, I believe that ESG is not just a corporate obligation but a reflection of our core values and aspirations. We are enthusiastic about our potential to make a positive impact in the world, from the patients we seek to help with innovative new treatments, to giving back to the communities in which we work and live.*

*I look forward to sharing updates on the advancements we make in our ESG journey. Thank you for your continued support as we advance on this path.”*

## WHAT IS IMPORTANT TO TANGO AND OUR STAKEHOLDERS

To create a strong foundation for our responsible business efforts and better understand which environmental, social, and governance topics are most important to associates and external stakeholders, we completed a double materiality assessment in 2024. We received input from an overwhelming majority of our associates, as well as stakeholders in disciplines including clinical testing, environmental sustainability, health and the environment, investing, medicines, oncology academics, and oncology research.

We asked participants to prioritize 17 topics, culled from a broader universe of responsible business principles. The topics that rose to the top are **bolded**.

- **Business Ethics**
- **Clinical Trial Safety**
- **Diversity, Equity, Inclusion, and Belonging**
- **Health Outcomes**
- **Patient Safety**
- **Regulatory Considerations**
- **Research & Development**
- Animal Testing
- Associate Engagement/ Company Culture
- Corporate/ESG Governance
- Employee Recruitment, Development, and Retention
- Environmental Footprint
- Office & Lab Safety
- Philanthropy/Community Engagement
- Privacy/Cybersecurity
- Supply Chain Management
- Workplace Health and Wellness

